Circulating Vascular Endothelial Growth Factor Six Months after Primary Surgery as a Prognostic Marker in Patients with Colorectal Cancer

Acta Oncologica

Volumn 42, Issue 8, 2003, Pages 837-845

  Werther, Kim ^a,c   Sørensen, Sten ^a   Christensen, Ib J ^b   Nielsen, Hans J ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CARCINOMA; COLORECTAL SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMA; POSTOPERATIVE PERIOD; PROGNOSIS; SERUM; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0347756676     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310003509     Document Type: Article

References (29)

1. Carriquiry LA, Pineyro A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum 1999; 42: 921-9.
2. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Br J Cancer 1999; 79: 1494-9.
3. Harrison LE, Guillem JG, Paty P, Cohen AM. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 1997; 185: 55-9.
4. Filella X, Molina R, Pique JM, et al. CEA as a prognostic factor in colorectal cancer. Anticancer Res 1994; 14: 705-8.
5. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 2001; 47: 624-30.
6. Werther K, Christensen IJ, Nielsen HJ. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 2002; 86: 417-23.
7. Michel P, Merle V, Chiron A, et al. Postoperative management of stage II/III cancer: a decision analysis. Gastroenterology 1999; 117: 784-93.
8. Broll R. Erdmann H, Duchrow M, et al. Vascular endothelial growth factor (VEGF) - a valuable serum tumour marker in patients with colorectal cancer? Eur J Surg Oncol 2001; 27: 37-42.
9. McDonnell CO, Harmey JH, Bouchier-Hayes DJ, Walsh TN. Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer. Br J Surg 2001; 88: 1105-9.
10. Oehler MK, Caffier H. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res 2000; 20: 5109-12.
11. Mishaeli M, Klein B, Sadikov E., et al. Initial TPS serum level as an indicator of relapse and survival in colorectal cancer. Anticancer Res 1998; 18: 2101-5.
12. Filella X, Molina R, Pique JM, et al. Use of CA 19-9 in the early detection of recurrences in colorectal cancer: comparison with CEA. Tumour Biol 1994; 15: 1-6.
13. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 2000; 20: 5195-8.
14. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000; 5(Suppl 1): 3-10.
15. Neufeld G, Kessler O, Vadasz Z, Gluzman-Poltorak Z. The contribution of proangiogenic factors to the progression of malignant disease: role of vascular endothelial growth factor and its receptors. Surg Oncol Clin N Am 2001; 10: 339-56, ix.
16. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50.
17. Via LE, Gore-Langton RE, Pluda JM. Clinical trials referral resource. Current clinical trials administering the antiangiogenesis agent SU5416. Oncology (Huntingt) 2000; 14: 1312, 1313-5.
18. Gordon MS. Vascular endothelial growth factor as a target for antiangiogenic therapy. J Clin Oncol 2000; 18(Suppl 21): 45S-6S.
19. Schlaeppi JM, Wood JM. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev 1999; 18: 473-81.
20. Zogakis TG, Libutti SK. General aspects of anti-angiogenesis and cancer therapy. Expert Opin Biol Ther 2001; 1: 253-75.
21. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001; 23: 263-72.
22. Gunzer M, Janich S, Varga G, Grabbe S. Dendritic cells and tumor immunity. Semin Immunol 2001; 13: 291-302.
23. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92: 4150-66.
24. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-201.
25. Hattori K, Dias S, Heissig B, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001; 193: 1005-14.
26. Kuroi K, Toi M. Circulating angiogenesis regulators in cancer patients. Int J Biol Markers 2001; 16: 5-26.
27. Shimoyama S, Yamasaki K, Kawahara M, Kaminishi M. Increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin Cancer Res 1999; 5: 1125-30.
28. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-25.
29. Marshall E. Cancer therapy Setbacks for endostatin. Science 2002; 295(5563): 2198-9.